Overview
Pemphigoid nodularis, often discussed alongside prurigo nodularis due to overlapping clinical features, is a chronic inflammatory skin condition characterized by intensely pruritic nodules 12. The exact patho-etiology remains unclear, complicating effective management 1.Diagnosis
Presence of firm, nodular skin lesions
Persistent pruritus lasting at least 6 weeks
History of repeated scratching, picking, or rubbing
Clinical signs and patient interviews for diagnosis 1
Comprehensive review of systems to rule out systemic diseases 2
Assessment of disease severity via number of nodules and intensity of itching 1Management
First-line treatments:
- Topical corticosteroids 1
- Antihistamines 1
Adjunctive treatments:
- Addressing neural and immunologic components of pruritus based on patient response and comorbidities 2
- Other therapies may include systemic immunosuppressants, phototherapy, or biologics, though specific dosing is not detailed in the abstracts 2Special Populations
Comorbidities: Management should consider comorbidities and prior treatment responses 2
Severity impact: Treatment satisfaction decreases with increasing severity, indicating a need for more effective therapies in severe cases 1Key Recommendations
Diagnose pemphigoid nodularis primarily through clinical signs and patient history, supplemented by systemic disease exclusion 12 (Evidence: Moderate)
Utilize topical corticosteroids and antihistamines as first-line treatments 1 (Evidence: Expert opinion)
Tailor treatment plans based on disease severity, patient comorbidities, and prior treatment responses to optimize outcomes 2 (Evidence: Moderate)References
1 Murota H, Matsumoto M, Arima K, Yoshida T, Fujita H. Current clinical practice of prurigo nodularis in Japan: A cross-sectional web-survey among dermatologists. The Journal of dermatology 2025. link
2 Elmariah S, Kim B, Berger T, Chisolm S, Kwatra SG, Mollanazar N et al.. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. Journal of the American Academy of Dermatology 2021. link